Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial

NCT03628391 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT03628391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03628391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial
Lead sponsor
Erasmus Medical Center
Phase
Phase 3
Overall status
Terminated
Start date
February 22, 2018
Completion date
January 23, 2021
Enrollment
142 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive decline, cognitive impairment, critical illness, delirium, intensive care psychosis